Application of 68Ga-NODAGA-SNA006 Positron Emission Tomography/Computed Tomography (PET/CT) in Tumors

China Medical University

Status and phase: Active, not recruiting; Phase 2; Phase 1

Conditions: Cancer

Treatments: Drug: 68Ga-NODAGA-SNA006

Study type: Interventional

Funder types: Other

Identifiers

NCT07059832

[2024]1161

Details and patient eligibility

About

This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the safety and clinical predictive value of 68Ga-NODAGA-SNA006 in subjects with solid tumor or lymphoma.

Full description

The aim of this study was to explore the safety and clinical predictive value of 68Ga-NODAGA-SNA006 in patients with solid tumors or lymphoma.

Enrollment: 30 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Participants who were diagnosed with malignant tumors;
2. Patients are between 18 and 80 years of age are between 18 and 80 years of age.

Exclusion criteria

1. Participants who were unable or unwilling to provide written informed consent.
2. Participants who were unable to successfully complete the examination and are forced to abort the test in the middle of the test

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

Feasibility and safety of 68Ga-NODAGA-SNA006

Experimental group

Description:

68Ga-NODAGA-SNA006 0.05 mCi/Kg, interval time between FDG was within five days

Treatment:

Drug: 68Ga-NODAGA-SNA006